AEON
AEON Biopharma, Inc.
Healthcare — Biotechnology
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
None
2 analysts
$0.28
$-0.02 (-7.67%)
Target:
$6.70
(2318.8%)
Price History
Sign in to add AEON to a watchlist or set price alerts.
Fundamentals
| Market Cap | $18.63M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.03 |
| EPS (TTM) | $-6.52 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $6.70 |
| Analysts | 2 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 48.3 |
| Beta | 0.61 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
NEUTRALAEON presents a mixed picture with both positive and negative indicators.
~
RSI at 48.3 is in neutral territory.
~
Wall Street consensus is "none" from 2 analysts.
+
Average analyst target of $6.70 implies 2318.8% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report